{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:49:12Z","timestamp":1784803752356,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The diversity and depth of clinical research in the field of infectious diseases in 2025 were impressive. Multiple new antibiotics were approved, innovative uses of technology to improve patient care were tested, and novel approaches were trialed to address longstanding problems in infectious diseases. Despite this progress, the resurgence of measles in 2025 offers a stark reminder that any progress against infectious diseases can quickly be lost if the principles of infectious diseases and public health are abandoned. Some of the most important clinical trials and trends in infectious diseases over the past year are highlighted in this review.<\/jats:p>","DOI":"10.1093\/cid\/ciaf740","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:43:38Z","timestamp":1767876218000},"page":"e705-e709","source":"Crossref","is-referenced-by-count":1,"title":["What's Hot This Year in ID Clinical Science 2025"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-1481","authenticated-orcid":false,"given":"Jeffrey A","family":"Freiberg","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]},{"name":"Vanderbilt Institute for Infection, Immunology, and Inflammation, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]},{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]},{"name":"United States Department of Veterans Affairs Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-6328","authenticated-orcid":false,"given":"Patty W","family":"Wright","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2026043013112515200_ciaf740-B1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026043013112515200_ciaf740-B2","doi-asserted-by":"crossref","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing gram-negative pathogens: a phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC-Antimicrob Resist"},{"key":"2026043013112515200_ciaf740-B3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026043013112515200_ciaf740-B4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026043013112515200_ciaf740-B5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cmi.2024.10.025","article-title":"A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections","volume":"31","author":"Dunne","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026043013112515200_ciaf740-B6","doi-asserted-by":"crossref","first-page":"EVIDoa2400414","DOI":"10.1056\/EVIDoa2400414","article-title":"Sulopenem versus amoxicillin\/clavulanate for the treatment of uncomplicated urinary tract infection","volume":"4","author":"Puttagunta","year":"2025","journal-title":"NEJM Evid"},{"key":"2026043013112515200_ciaf740-B7","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"The Lancet"},{"key":"2026043013112515200_ciaf740-B8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial","volume":"334","author":"Turner","year":"2025","journal-title":"JAMA"},{"key":"2026043013112515200_ciaf740-B9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7326\/ANNALS-24-03285","article-title":"Fecal microbiota transplantation versus vancomycin for primary Clostridioides difficile infection: a randomized controlled trial","volume":"178","author":"Juul","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026043013112515200_ciaf740-B10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa2405404","article-title":"Male-partner treatment to prevent recurrence of bacterial vaginosis","volume":"392","author":"Vodstrcil","year":"2025","journal-title":"N Engl J Med"},{"key":"2026043013112515200_ciaf740-B11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2404991","article-title":"Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections","volume":"392","author":"Daneman","year":"2025","journal-title":"N Engl J Med"},{"key":"2026043013112515200_ciaf740-B12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2024.26458","article-title":"Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: the ADAPT-sepsis randomized clinical trial","volume":"333","author":"Dark","year":"2025","journal-title":"JAMA"},{"key":"2026043013112515200_ciaf740-B13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1473-3099(25)00075-1","article-title":"Efficacy and safety of individualised versus standard 10-day antibiotic treatment in children with febrile urinary tract infection (INDI-UTI): a pragmatic, open-label, multicentre, randomised, controlled, non-inferiority trial in Denmark","volume":"25","author":"Sethi","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026043013112515200_ciaf740-B14","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/jamainternmed.2025.0887","article-title":"Improving empiric antibiotic selection for patients hospitalized with skin and soft tissue infection: the INSPIRE 3 skin and soft tissue randomized clinical trial","volume":"185","author":"Gohil","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2026043013112515200_ciaf740-B15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/jamasurg.2025.1108","article-title":"Improving empiric antibiotic selection for patients hospitalized with abdominal infection: the INSPIRE 4 cluster randomized clinical trial","volume":"160","author":"Gohil","year":"2025","journal-title":"JAMA Surg"},{"key":"2026043013112515200_ciaf740-B16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cid\/ciae520","article-title":"Peer-assisted telemedicine for hepatitis C in people who use drugs: a randomized controlled trial","volume":"80","author":"Seaman","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026043013112515200_ciaf740-B17","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.2024.21060","article-title":"Electronic nudges to increase influenza vaccination in patients with chronic diseases: a randomized clinical trial","volume":"332","author":"Johansen","year":"2024","journal-title":"JAMA"},{"key":"2026043013112515200_ciaf740-B18","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","article-title":"Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination","volume":"391","author":"Muyembe","year":"2024","journal-title":"N Engl J Med"},{"key":"2026043013112515200_ciaf740-B19","author":"CDC"},{"key":"2026043013112515200_ciaf740-B20","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1001\/jama.2025.6495","article-title":"Modeling reemergence of vaccine-eliminated infectious diseases under declining vaccination in the US","volume":"333","author":"Kiang","year":"2025","journal-title":"JAMA"},{"key":"2026043013112515200_ciaf740-B21","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","article-title":"Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam","volume":"391","author":"Fox","year":"2024","journal-title":"N Engl J Med"},{"key":"2026043013112515200_ciaf740-B22","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","article-title":"Levofloxacin preventive treatment in children exposed to MDR tuberculosis","volume":"391","author":"Hesseling","year":"2024","journal-title":"N Engl J Med"},{"key":"2026043013112515200_ciaf740-B23","doi-asserted-by":"crossref","first-page":"EVIDoa2400190","DOI":"10.1056\/EVIDoa2400190","article-title":"A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis","volume":"4","author":"Duong","year":"2025","journal-title":"NEJM Evid"},{"key":"2026043013112515200_ciaf740-B24","volume-title":"Everything is tuberculosis: the history and persistence of our deadliest infection","author":"Green","year":"2025"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf740\/66319727\/ciaf740.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e705\/66319727\/ciaf740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e705\/66319727\/ciaf740.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:11:34Z","timestamp":1777569094000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/e705\/8417748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf740","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2026,1,9]]}}}